Relmada Therapeutics Inc

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Relmada Therapeutics addresses setbacks, remains confident in REL-1017's potential

Relmada Therapeutics faced challenges in Q4 2022 with study results, leading to increased expenses and a net loss. Despite setbacks, the company remains confident in REL-1017's potential and is focused on refining trial protocols for future success.

Relmada Therapeutics reports positive Q1 results and advances MDD treatment

Relmada Therapeutics Inc. demonstrates financial improvement and progress in its REL-1017 program for major depressive disorder. The company's strategic amendments to study protocols and upcoming safety study data release indicate a commitment to advancing its pipeline. Addressing challenges in trial management and regulatory interactions is key to sustaining growth and market success.

Relmada Therapeutics reports improved Q2 financials and advances in key trials

Relmada Therapeutics showcased improved financial performance and progress in key clinical trials during the Q2 2023 Earnings Call.
While challenges like enrollment progress and regulatory feedback exist, the company's adaptability and cash position provide strengths to navigate them.
Opportunities lie in expanding the clinical program, achieving positive trial outcomes, and enhancing investor confidence through transparent communication.

Relmada Therapeutics reports positive Q3 results and advances key programs

Relmada Therapeutics demonstrated strong performance in Q3 2023 with progress in key programs and improved financial metrics.
While facing challenges in expense management and trial timelines, the company's strengths in research and financial discipline position them well for future growth.
Opportunities lie in leveraging positive trial results, attracting investors, and advancing innovative treatments to drive value creation.

Relmada Therapeutics reports progress in Phase III programs and financial stability

Relmada Therapeutics Inc showcased positive performance in its Phase III program and financial results, demonstrating resilience and strategic planning. While challenges exist in enrollment and monitoring, the company's confidence in its products and innovative approach to psilocybin present promising opportunities for growth and development.

Relmada Therapeutics Inc reports strong Q1 performance and pipeline advancements

Relmada Therapeutics Inc reported positive financial performance, progress in key programs, and proactive pipeline expansion in Q1 2024, positioning the company for future growth.
While facing challenges such as increased screening failure rates and competition, Relmada's strategic focus on trial optimization and therapeutic innovation presents opportunities for advancement.
The company's commitment to addressing mental health needs through Phase III trials and novel programs like psilocybin underscores its dedication to driving clinical progress and market differentiation.
With a strong financial position and promising developments in the pipeline, Relmada is poised to navigate challenges, capitalize on opportunities, and drive value for stakeholders.

Relmada Therapeutics advances CNS disorder treatments amidst financial stability

Relmada Therapeutics is making strides in advancing treatments for CNS disorders, with a focus on major depressive disorder. Financially, the company is managing expenses while progressing key programs. Uncertainty around interim analysis outcomes presents challenges, but successful results could open doors to new opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Shares of Relmada Therapeutics Inc. RLMD, -0.97% fell 80.0% in premarket trading on Thursday after the biotech said its experimental treatment for major depressive disorder as a monotherapy did not meet the primary endpoint in a Phase 3 clinical trial. The company said it is still enrolling patients in two other late-stage studies assessing the therapy as an adjunctive treatment.

Relmada's stock tumbles 80% after its depressive disorder drug failed a late-stage study

RELIANCE I and II Adjunctive MDD Trials Continue to Advance CORAL GABLES, Fla. , Oct. 13, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that its RELIANCE III study (REL-1017-303), evaluating REL-1017 in the monotherapy setting for Major Depressive Disorder (MDD), did not achieve its primary endpoint, which was a statistically significant improvement in depression symptoms compared to placebo as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) on Day 28.

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

100% technical buy signals. 8 new highs and up 15.55% in the last month.

Relmada Therapeutics: Central Nervous System Treatments

CORAL GABLES, Fla. , Sept. 20, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the completion of patient treatment in RELIANCE III, a monotherapy registrational Phase 3 trial evaluating REL-1017, the Company's novel NMDA receptor (NMDAR) channel blocker, for major depressive disorder (MDD).

Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder

Aerie Pharmaceuticals

Belite Bio Inc

Chemocentryx

Catalyst Pharmaceuticals

Verona Pharma

Akero Therapeutics Inc

Gossamer Bio Inc

Viridian Therapeutics

Ventyx Biosciences

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year appeared first on Investor's Business Daily.

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

We initiate Relmada Therapeutics with a Strong BUY rating due to our high degree of conviction on REL-1017's clinical success during the phase 3 trial. The phase 2 data showed that REL-1017 is rapid, effective, safe, and durable.

Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Sergio Traversa - Chief Executive Officer John Hixon - Head of Commercial Maged Shenouda - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Yatin Suneja - Guggenheim Andrea Tan - Goldman Sachs Joon Lee - Truist Securities Jay Olson - Oppenheimer Uy Ear - Mizuho Securities Operator Good day, ladies and gentlemen, and welcome to the Relmada Therapeutics, Inc. Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded.

Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q2 2022 Results - Earnings Call Transcript

CORAL GABLES, Fla. , Aug. 11, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD) ("Relmada," the "Company," "we," "us, "our"), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the three and six months ended June 30, 2022.

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

CORAL GABLES, Fla. , Aug. 9, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to REL-1017, the Company's novel NMDA receptor (NMDAR) channel blocker, as a monotherapy for the treatment major depressive disorder (MDD).

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

CORAL GABLES, Fla. , Aug. 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter and six months ended June 30, 2022, after the market close on Thursday, August 11, 2022.

Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022 CORAL GABLES, Fla. , July 21, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of John Hixon to a newly created position as Head of Commercial.

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

CORAL GABLES, Fla. , June 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 10:40am PT / 1:40pm ET.

Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

CORAL GABLES, Fla. , June 2, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference on Wednesday, June 8, 2022, at 4:00pm ET.

Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

CORAL GABLES, Fla., May 25, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company's lead product candidate, will be presented virtually in two poster presentations at the American Society of Clinical Psychopharmacology 2022 Annual Meeting.

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors, Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Andrea Tan - Goldman Sachs Yatin Suneja - Guggenheim Partners Marc Goodman - SVB Leerink Vamil Divan - Mizuho Securities Matt Hershenhorn - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. And welcome to the Relmada Therapeutics, Inc. First Quarter 2022 Earnings Call.

Relmada Therapeutics, Inc.'s (RLMD) CEO Sergio Traversa on Q1 2022 Results - Earnings Call Transcript

CORAL GABLES, Fla. , May 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2022.

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

CORAL GABLES, Fla. , April 29, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today the publication of REL-1017 preclinical data in the peer-reviewed journal, Frontiers in Pharmacology.

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

CORAL GABLES, Fla. , April 28, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2022 after the market close on Thursday, May 5, 2022.

Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

CORAL GABLES, Fla. , April 4, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company's lead product candidate, will be presented in two poster presentations and one oral presentation at the Ketamine & Related Compounds International Hybrid Conference 2022.

Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022

Relmada Therapeutics Inc (NASDAQ: RLMD) shares are trading higher by 7.2% at $25.01 after the company reported better-than-expected fourth-quarter EPS results. Relmada Therapeutics reported quarterly losses of $1.80 per share which beat the analyst consensus estimate of a loss of $1.83.

Here's Why Relmada Therapeutics Shares Are Rising

Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q4 2021 Results - Earnings Call Transcript

CORAL GABLES, Fla., March 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2021.

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

CORAL GABLES, Fla., March 16, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021 after the market close on Wednesday, March 23, 2022.

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022

CORAL GABLES, Fla., March 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in fireside chats at Needham & Company's 1st Annual Neuroscience Forum and Oppenheimer's 32nd Annual Healthcare Conference, taking place March 16th, 2022 at 9:30am ET and March 17th, 2022 at 1:20pm ET, respectively.

Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events

Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD. REL-1017 is a novel NMDA receptor (NMDAR) channel blocker and the Company's lead candidate.

News for Relmada Therapeutics Inc Stock (RLMD)